A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer
暂无分享,去创建一个
[1] Q. Qu,et al. The Effects of Lycopene on the Methylation of the GSTP1 Promoter and Global Methylation in Prostatic Cancer Cell Lines PC3 and LNCaP , 2014, International journal of endocrinology.
[2] J. Korbel,et al. Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer , 2014, International journal of cancer.
[3] Michael V. Fiandalo,et al. Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment , 2014, International journal of biological sciences.
[4] E. Antonarakis,et al. Castration-resistant prostate cancer: latest evidence and therapeutic implications , 2014, Therapeutic advances in medical oncology.
[5] J. Dunford,et al. Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. , 2014, Chemico-biological interactions.
[6] J. Ferlay,et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.
[7] N. Kyprianou,et al. Androgen regulation of epithelial–mesenchymal transition in prostate tumorigenesis , 2011, Expert review of endocrinology & metabolism.
[8] M. Negri,et al. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development , 2011, The Journal of Steroid Biochemistry and Molecular Biology.
[9] Allen D. Delaney,et al. LNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer , 2010, BMC Medical Genomics.
[10] Liang Cheng,et al. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. , 2010, Human pathology.
[11] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[12] Manoj Bhasin,et al. Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer , 2009, Clinical Cancer Research.
[13] Janet M Thornton,et al. The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. , 2009, Chemico-biological interactions.
[14] H. Tutill,et al. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. , 2008, Endocrine-related cancer.
[15] Loredana Moro,et al. Loss of BRCA2 promotes prostate cancer cell invasion through up‐regulation of matrix metalloproteinase‐9 , 2008, Cancer science.
[16] D. Grignon,et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. , 2007, International journal of radiation oncology, biology, physics.
[17] R. Hynes,et al. Protein 4.1B suppresses prostate cancer progression and metastasis , 2007, Proceedings of the National Academy of Sciences.
[18] R. Abaza,et al. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy. , 2006, The Journal of urology.
[19] J. Adamski,et al. Bioinformatic identification and characterization of new members of short-chain dehydrogenase/reductase superfamily , 2006, Molecular and Cellular Endocrinology.
[20] M. Sadar,et al. Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.
[21] M. Hewison,et al. 11β-Hydroxysteroid dehydrogenases, cell proliferation and malignancy , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[22] L. Bubendorf,et al. Tissue microarray analysis reveals prognostic significance of syndecan‐1 expression in prostate cancer , 2003, The Prostate.
[23] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[24] G. Christofori,et al. The tumor-suppressor function of E-cadherin. , 1998, American journal of human genetics.
[25] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[26] M. Erdos,et al. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins , 1998, Oncogene.
[27] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[28] G. Murphy,et al. LNCaP model of human prostatic carcinoma. , 1983, Cancer research.
[29] A. Jemal,et al. Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.
[30] R. Dahiya,et al. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1 , 2007, In Vitro Cellular & Developmental Biology - Animal.
[31] John T. Wei,et al. Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.
[32] K. Palczewski,et al. Short-chain dehydrogenases/reductases in retina. , 2000, Methods in enzymology.
[33] R. Kath,et al. [Tumor progression and metastasis]. , 1990, Zentralblatt fur Chirurgie.